Caris Life Sciences (CAI) Cash & Current Investments (2024 - 2026)

Caris Life Sciences' Cash & Current Investments history runs 3 years deep, the most recent figure standing at $823.5 million for Q1 2026.

• On a quarterly basis, Cash & Current Investments changed N/A year-over-year to $823.5 million in Q1 2026; TTM through Mar 2026 was $823.5 million, a N/A change from a year earlier, with the FY2025 full-year figure at $800.1 million, up 1082.82% from the prior year.
• Cash & Current Investments improved to $823.5 million in Q1 2026 per CAI's latest filing, from $800.1 million in the prior quarter.
• Across five years, Cash & Current Investments topped out at $823.5 million in Q1 2026 and bottomed at $67.6 million in Q4 2024.
• The 3-year median for Cash & Current Investments is $757.0 million (2025), against an average of $634.0 million.
• Biggest YoY gain for Cash & Current Investments was 1082.82% in 2025; the steepest drop was 1082.82% in 2025.
• Year by year, Cash & Current Investments stood at $67.6 million in 2024, then jumped by 1082.82% to $800.1 million in 2025, then rose by 2.92% to $823.5 million in 2026.
• Per Business Quant, the three latest CAI Cash & Current Investments figures stand at $823.5 million (Q1 2026), $800.1 million (Q4 2025), and $757.0 million (Q3 2025).